FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011514705> ?p ?o ?g. }

• W3011514705 abstract "Abstract Background Chemokine C–C motif ligand 2 (CCL2) is one of the most widely recognised proinflammatory chemokines in cognitive disorders. Currently, CCL2-targeting drugs are extremely limited. Thus, this study aimed to explore the neuroprotection afforded by naringin in CCL2-induced cognitive impairment in rats. Methods Before the CCL2 intra-hippocampal injection, rats were treated with naringin for 3 consecutive days via intraperitoneal injection. Two days post-surgery, the Morris water maze (MWM) and novel object recognition (NORT) tests were performed to detect spatial learning and memory and object cognition, respectively. Nissl staining and dUTP nick-end labelling (TUNEL) staining were performed to assess histopathological changes in the hippocampus. Commercial kits were used to measure the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and the content of malondialdehyde (MDA). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to examine the relative mRNA expression of interleukin 1β, (IL-1β), interleukin 6 (IL-6), glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT-1), phosphate-activated glutaminase (PAG), cysteine aspartic acid-specific protease 8 (caspase-8), cysteine aspartic acid-specific protease 3 (caspase-3), cell lymphoma/leukaemia-2 (Bcl-2), and Bcl-2 associated X protein (Bax). Results In the MWM, the average escape latency and average swimming distance were significantly reduced and the crossing times were increased in the naringin-treated groups, compared with the CCL2 group. The NORT results revealed that, compared with the CCL2 rats, the discrimination index in the naringin-treated rats increased significantly. Nissl and TUNEL staining revealed that naringin protected the structure and survival of the neurons in the CA1 zone of the hippocampus. In the naringin-treated groups, the SOD and GSH-Px activities were increased, whereas the MDA levels were decreased. Furthermore, in the naringin-treated groups, the relative mRNA expression of IL-1β and IL-6 was significantly decreased; GLAST and GLT-1 mRNA expression levels were increased, whereas PAG was decreased. In the naringin-treated groups, the relative mRNA expression levels of caspase-8, caspase-3, and Bax were decreased, whereas that of Bcl-2 was increased. Conclusion Collectively, these data indicated that naringin alleviated the CCL2-induced cognitive impairment. The underlying mechanisms could be associated with the inhibition of neuroinflammation, oxidative stress, apoptosis, and the regulation of glutamate metabolism." @default.
• W3011514705 created "2020-03-23" @default.
• W3011514705 creator A5007014008 @default.
• W3011514705 creator A5009249209 @default.
• W3011514705 creator A5010058611 @default.
• W3011514705 creator A5014107541 @default.
• W3011514705 creator A5032456908 @default.
• W3011514705 creator A5081954261 @default.
• W3011514705 date "2020-02-27" @default.
• W3011514705 modified "2023-10-08" @default.
• W3011514705 title "Naringin provides neuroprotection in CCL2-induced cognition impairment by attenuating neuronal apoptosis in the hippocampus" @default.
• W3011514705 cites W1528808657 @default.
• W3011514705 cites W1819303234 @default.
• W3011514705 cites W1934973931 @default.
• W3011514705 cites W1963721982 @default.
• W3011514705 cites W1976421149 @default.
• W3011514705 cites W1988856395 @default.
• W3011514705 cites W1994580609 @default.
• W3011514705 cites W1994662730 @default.
• W3011514705 cites W2032474965 @default.
• W3011514705 cites W2038966471 @default.
• W3011514705 cites W2043849781 @default.
• W3011514705 cites W2048057207 @default.
• W3011514705 cites W2067645235 @default.
• W3011514705 cites W2070337941 @default.
• W3011514705 cites W2076255624 @default.
• W3011514705 cites W2091665736 @default.
• W3011514705 cites W2108369287 @default.
• W3011514705 cites W2110488126 @default.
• W3011514705 cites W2130964059 @default.
• W3011514705 cites W2135035597 @default.
• W3011514705 cites W2156586619 @default.
• W3011514705 cites W2179846566 @default.
• W3011514705 cites W2200746626 @default.
• W3011514705 cites W2266635609 @default.
• W3011514705 cites W2297151425 @default.
• W3011514705 cites W2345603894 @default.
• W3011514705 cites W2470659555 @default.
• W3011514705 cites W2560905683 @default.
• W3011514705 cites W2587701879 @default.
• W3011514705 cites W2620901112 @default.
• W3011514705 cites W2735609145 @default.
• W3011514705 cites W2746831366 @default.
• W3011514705 cites W2772400483 @default.
• W3011514705 cites W2782565874 @default.
• W3011514705 cites W2784023565 @default.
• W3011514705 cites W2784203112 @default.
• W3011514705 cites W2804284220 @default.
• W3011514705 cites W2807141429 @default.
• W3011514705 cites W2887233089 @default.
• W3011514705 cites W2891208481 @default.
• W3011514705 cites W2943705760 @default.
• W3011514705 cites W2944548468 @default.
• W3011514705 cites W317730081 @default.
• W3011514705 cites W824407160 @default.
• W3011514705 doi "https://doi.org/10.1186/s12993-020-00166-6" @default.
• W3011514705 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7045422" @default.
• W3011514705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32103758" @default.
• W3011514705 hasPublicationYear "2020" @default.
• W3011514705 type Work @default.
• W3011514705 sameAs 3011514705 @default.
• W3011514705 citedByCount "14" @default.
• W3011514705 countsByYear W30115147052020 @default.
• W3011514705 countsByYear W30115147052021 @default.
• W3011514705 countsByYear W30115147052022 @default.
• W3011514705 countsByYear W30115147052023 @default.
• W3011514705 crossrefType "journal-article" @default.
• W3011514705 hasAuthorship W3011514705A5007014008 @default.
• W3011514705 hasAuthorship W3011514705A5009249209 @default.
• W3011514705 hasAuthorship W3011514705A5010058611 @default.
• W3011514705 hasAuthorship W3011514705A5014107541 @default.
• W3011514705 hasAuthorship W3011514705A5032456908 @default.
• W3011514705 hasAuthorship W3011514705A5081954261 @default.
• W3011514705 hasBestOaLocation W30115147051 @default.
• W3011514705 hasConcept C126322002 @default.
• W3011514705 hasConcept C134018914 @default.
• W3011514705 hasConcept C142724271 @default.
• W3011514705 hasConcept C185592680 @default.
• W3011514705 hasConcept C190283241 @default.
• W3011514705 hasConcept C196795494 @default.
• W3011514705 hasConcept C25498285 @default.
• W3011514705 hasConcept C2781161787 @default.
• W3011514705 hasConcept C37753355 @default.
• W3011514705 hasConcept C44752575 @default.
• W3011514705 hasConcept C55493867 @default.
• W3011514705 hasConcept C71924100 @default.
• W3011514705 hasConcept C74864618 @default.
• W3011514705 hasConcept C98274493 @default.
• W3011514705 hasConceptScore W3011514705C126322002 @default.
• W3011514705 hasConceptScore W3011514705C134018914 @default.
• W3011514705 hasConceptScore W3011514705C142724271 @default.
• W3011514705 hasConceptScore W3011514705C185592680 @default.
• W3011514705 hasConceptScore W3011514705C190283241 @default.
• W3011514705 hasConceptScore W3011514705C196795494 @default.
• W3011514705 hasConceptScore W3011514705C25498285 @default.
• W3011514705 hasConceptScore W3011514705C2781161787 @default.
• W3011514705 hasConceptScore W3011514705C37753355 @default.
• W3011514705 hasConceptScore W3011514705C44752575 @default.
• W3011514705 hasConceptScore W3011514705C55493867 @default.
• W3011514705 hasConceptScore W3011514705C71924100 @default.

• next